Berwyn, Pennsylvania--(Newsfile Corp. - March 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the Japan Patent Office (JPO) granted the Company's patent (2018-527851) for the treatment or prevention of acute brain or nerve injury by administering ANVS405.
"This new patent further strengthens our intellectual property focused on the treatment of neurodegenerative diseases," commented Maria Maccecchini, Ph.D., CEO of Annovis. "We believe there are additional opportunities to expand our patent coverage both globally and in the US. While in Europe and Japan we received a patent for all acute indications (stroke, traumatic brain injury, spinal cord injury and nerve injury), in the US we have filed divisional applications for each indication separately with the US Patent and Trademark Office (USPTO) and we look forward to providing updates as new allowances are granted in the future."
The Company received its first PD patent (US 10,383,851) from the USPTO in August 2019 and its first AD patent (EP 2683242) from the European Patent Office (EPO) in March 2020. The EPO approved Annovis Bio's first acute patent (EP 3334425B1) in December 2020.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: .
Forward-Looking Statements
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials and the approval of any allowances or additional patents. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including the risk that additional patent allowances may not be received. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
SOURCE: Annovis Bio, Inc.
To view the source version of this press release, please visit
